BiDil: Phase III data

Data from the 18-month, double-blind, placebo-controlled Phase III A-HeFT trial in 1,050 patients showed

Read the full 149 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE